Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
107M
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
6.2M
-
Shares change
-
+802K
-
Total reported value, excl. options
-
$6.44M
-
Value change
-
+$751K
-
Put/Call ratio
-
0.03
-
Number of buys
-
14
-
Number of sells
-
-12
-
Price
-
$1.04
Significant Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) as of Q4 2024
42 filings reported holding SLS - SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.2M shares
of 107M outstanding shares and own 5.81% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (2.29M shares), Anson Funds Management LP (1.19M shares), GEODE CAPITAL MANAGEMENT, LLC (734K shares), CITADEL ADVISORS LLC (485K shares), BlackRock, Inc. (444K shares), Opus Capital Group, LLC (239K shares), STATE STREET CORP (228K shares), NORTHERN TRUST CORP (135K shares), UBS Group AG (128K shares), and XTX Topco Ltd (53.4K shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.